• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

STING-ATF3/type I interferon crosstalk: A potential target to improve anti-tumour immunity in chemotherapy-treated urothelial carcinoma.

作者信息

Fauvre Alexandra, Machu Margot, Merienne Audrey, Vie Nadia, Bessede Thomas, Robin Mathilde, Garambois Veronique, Taffoni Clara, Laguette Nadine, Gervois-Segain Nadine, Jarry Anne, Labarriere Nathalie, Allory Yves, Larbouret Christel, Gros Laurent, Tosi Diego, Solit David B, Pourquier Philippe, Houédé Nadine, Gongora Celine

机构信息

IRCM, Univ Montpellier, Inserm, ICM, CNRS, Montpellier, France.

Nantes Université, Univ Angers, INSERM, CNRS, Nantes, France.

出版信息

Clin Transl Med. 2024 Sep;14(9):e70011. doi: 10.1002/ctm2.70011.

DOI:10.1002/ctm2.70011
PMID:39269751
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11397130/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0969/11397130/482d023240eb/CTM2-14-e70011-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0969/11397130/bb6854b803e6/CTM2-14-e70011-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0969/11397130/99858d247cae/CTM2-14-e70011-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0969/11397130/482d023240eb/CTM2-14-e70011-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0969/11397130/bb6854b803e6/CTM2-14-e70011-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0969/11397130/99858d247cae/CTM2-14-e70011-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0969/11397130/482d023240eb/CTM2-14-e70011-g002.jpg

相似文献

1
STING-ATF3/type I interferon crosstalk: A potential target to improve anti-tumour immunity in chemotherapy-treated urothelial carcinoma.STING-ATF3/Ⅰ型干扰素相互作用：改善化疗治疗的尿路上皮癌抗肿瘤免疫的潜在靶点
Clin Transl Med. 2024 Sep;14(9):e70011. doi: 10.1002/ctm2.70011.
2
No Longer A One-Trick Pony: STING Signaling Activity Beyond Interferon.不再是一招鲜：STING 信号转导活动超越干扰素。
J Mol Biol. 2022 Mar 30;434(6):167257. doi: 10.1016/j.jmb.2021.167257. Epub 2021 Oct 8.
3
[Antibody-Drug Conjugates against Urothelial Carcinoma-Current Issues and Future Development].[抗尿路上皮癌的抗体药物偶联物——当前问题与未来发展]
Gan To Kagaku Ryoho. 2024 Jul;51(7):691-694.
4
Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.抗程序性死亡配体1/转化生长因子β受体2（M7824）融合蛋白诱导人膀胱癌细胞系的免疫原性调节，使其更容易受到免疫介导的识别和裂解。
Urol Oncol. 2018 Mar;36(3):93.e1-93.e11. doi: 10.1016/j.urolonc.2017.09.027. Epub 2017 Nov 2.
5
[Immunooncology in Urologic Cancers: Current Status].[泌尿生殖系统癌症的免疫肿瘤学：现状]
Aktuelle Urol. 2016 Sep;47(5):374-7. doi: 10.1055/s-0042-113527. Epub 2016 Sep 28.
6
Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm.检查点抑制剂与尿路上皮癌：转化范例
Oncology (Williston Park). 2016 Feb;30(2):160-2, 176.
7
The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.尿路上皮癌中免疫检查点抑制的现状：当前证据与未来探索领域
Cancer J. 2016 Mar-Apr;22(2):96-100. doi: 10.1097/PPO.0000000000000175.
8
STING Signaling in Cancer Cells: Important or Not?STING 信号在癌细胞中的作用：重要还是不重要？
Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):125-132. doi: 10.1007/s00005-017-0481-7. Epub 2017 Jul 26.
9
Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non-Small Cell Lung Carcinoma Cells.激活转录因子3的诱导与非小细胞肺癌细胞中顺铂反应性相关。
Neoplasia. 2016 Sep;18(9):525-35. doi: 10.1016/j.neo.2016.07.004.
10
The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: will immunotherapy solve the problem?尿路上皮癌新辅助和辅助治疗的困境：免疫疗法能解决问题吗？
Immunotherapy. 2022 Mar;14(4):171-174. doi: 10.2217/imt-2021-0324. Epub 2022 Jan 10.

本文引用的文献

1
Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature.下一代测序时代的上尿路尿路上皮癌的分子特征：当前文献的系统评价。
Eur Urol. 2020 Aug;78(2):209-220. doi: 10.1016/j.eururo.2020.05.039. Epub 2020 Jun 20.
2
Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications.I型干扰素与癌症：一个需要新型临床应用的不断发展的故事。
Cancers (Basel). 2019 Dec 4;11(12):1943. doi: 10.3390/cancers11121943.
3
Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
合理开发结直肠癌化疗与分子靶向药物协同联合方案。
BMC Cancer. 2018 Aug 13;18(1):812. doi: 10.1186/s12885-018-4712-z.
4
The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer.cGAS-cGAMP-STING 通路将 DNA 损伤与炎症、衰老和癌症联系起来。
J Exp Med. 2018 May 7;215(5):1287-1299. doi: 10.1084/jem.20180139. Epub 2018 Apr 5.
5
ATF3 Is a Key Regulator of Macrophage IFN Responses.ATF3是巨噬细胞IFN反应的关键调节因子。
J Immunol. 2015 Nov 1;195(9):4446-55. doi: 10.4049/jimmunol.1500204. Epub 2015 Sep 28.
6
Upper tract urothelial neoplasms: incidence and survival during the last 2 decades.上尿路尿路上皮肿瘤：过去20年的发病率和生存率
J Urol. 2000 Nov;164(5):1523-5.